Shares of Pacira Biosciences Inc (NASDAQ:PCRX) have been given an average rating of “Buy” by the eighteen brokerages that are covering the stock, Marketbeat Ratings reports. Five equities research analysts have rated the stock with a hold recommendation and eleven have given a buy recommendation to the company. The average 12 month price objective among analysts that have covered the stock in the last year is $53.40.
A number of brokerages have issued reports on PCRX. BidaskClub raised shares of Pacira Biosciences from a “hold” rating to a “buy” rating in a report on Friday, May 8th. Stifel Nicolaus dropped their price objective on Pacira Biosciences from $49.00 to $48.00 and set a “hold” rating on the stock in a report on Thursday, May 7th. Zacks Investment Research downgraded Pacira Biosciences from a “buy” rating to a “hold” rating and set a $38.00 target price for the company. in a research note on Friday, March 27th. Royal Bank of Canada reiterated a “buy” rating and set a $56.00 price target on shares of Pacira Biosciences in a research report on Wednesday, May 13th. Finally, TheStreet upgraded shares of Pacira Biosciences from a “d+” rating to a “c-” rating in a research report on Monday, May 11th.
In other news, insider Roy Winston acquired 2,500 shares of the business’s stock in a transaction dated Wednesday, March 11th. The stock was purchased at an average cost of $36.50 per share, for a total transaction of $91,250.00. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, VP Lauren Bullaro Riker sold 2,000 shares of the stock in a transaction dated Tuesday, May 19th. The shares were sold at an average price of $42.81, for a total value of $85,620.00. Following the transaction, the vice president now owns 12,464 shares in the company, valued at $533,583.84. The disclosure for this sale can be found here. Company insiders own 5.80% of the company’s stock.
Pacira Biosciences stock traded up $0.02 during midday trading on Monday, reaching $45.10. The stock had a trading volume of 529,768 shares, compared to its average volume of 619,202. The firm has a market capitalization of $1.90 billion, a PE ratio of 38.86, a P/E/G ratio of 1.51 and a beta of 1.31. Pacira Biosciences has a 12 month low of $27.46 and a 12 month high of $51.35. The company has a quick ratio of 4.63, a current ratio of 5.37 and a debt-to-equity ratio of 0.94. The firm’s 50-day moving average price is $38.53 and its 200 day moving average price is $41.90.
Pacira Biosciences (NASDAQ:PCRX) last posted its quarterly earnings results on Thursday, May 7th. The company reported $0.53 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.30 by $0.23. The company had revenue of $105.68 million for the quarter, compared to analyst estimates of $101.64 million. Pacira Biosciences had a negative net margin of 0.02% and a positive return on equity of 13.89%. The company’s quarterly revenue was up 15.7% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.22 earnings per share. Equities research analysts expect that Pacira Biosciences will post 0.9 EPS for the current year.
Pacira Biosciences Company Profile
Pacira BioSciences, Inc provides non-opioid pain management and regenerative health solutions for health care practitioners and their patients in the United States. The company develops products based on its proprietary DepoFoam product delivery technology that encapsulates drugs without altering their molecular structure.
Featured Story: Why are trading ranges significant?
Receive News & Ratings for Pacira Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacira Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.